Based on currently available data, the main results of the meta-analysis are usually as follows: 1) Bone marrow-derived stem cell therapy might have reduced mortality rate and provided mild-to-moderate benefits within cardiac systolic function at mid-term follow-up for individuals with NIDCM; 2) this therapy produced no noticed improvement in exercise capacity.

NIDCM, an end-stage cardiomyopathy without coronary artery condition, often progresses into symptomatic HF due to a lack of efficient pharmaceutics and interventional strategies. Patients with NIDCM display a 31% mortality rate [ 17 ]. Thus, decreasing this mortality rate is critical. At present, the major treatments designed for NIDCM are medication and heart transplantation. However , because of the limited curative effects and poor prognoses associated with these types of approaches, stem cell therapy has become a focus of scientific research [ 18 ].

With this systematic review, a promising result was obtained; mortality price decreased more in the stem cell group than in the particular control group during 12 to 60  months associated with follow-up. With respect to left ventricular systolic function, stem cellular therapy did not significantly improve LVEF until after mid-term (6– 12 months) follow-up (a 3. 53% embrace LVEF). Consistently, reduced end-systolic left ventricular chamber dimension was not observed until after 6  months of followup. We hypothesize that the “ delayed” nature of LVEF enhancement might be due to cardiac remodelling mechanisms. Paracrine come cell mechanisms, rather than mechanisms of the transplanted cells on their own, play important roles in LVEF improvement [ 19 , 20 ]. Anti-inflammatory, immunomodulatory, and antioxidant activities play critical functions in reversing cardiac remodelling. Recent studies [ 21 , 22 ] have demonstrated that stem cell transplantation may prevent remodelling and stimulate reverse left ventricular re-designing, a process that requires an average of 3 to 12  months. Studies have suggested that, in addition to paracrine effects, other effects, like the mircrine phenomenon, contribute to the therapeutic effects of stem cellular material. In this phenomenon, miR-499-overexpressing human cardiac stem cells are usually regarded as “ donors”, and nearby cardiac stem cellular material serve as “ recipients”. Observations of connexin 43 have got suggested the potential translocation of miR-499 via gap junction channels. This new mode of cell-to-cell communication is called mircrine communication, which also requires time to affect tissue [ 23 ]. Interestingly, the results from cell therapy designed for ICM suggest a similar magnitude of LVEF improvement yet more rapid LVEF recovery [ 16 , 24 , 25 ]. Differences in the starting point time of cell therapy may be attributed to mechanisms that lead to the progression of NIDCM and ICM. By description, the most conspicuous difference between ICM and NIDCM could be the existence of atherosclerotic lesions in the epicardial coronary arterial blood vessels in patients with ICM and the absence of such skin lesions in patients with NIDCM. In theory, these lesions generate sufficient homing signals to induce stem cell engraftment in the damaged myocardium. Another abnormality in ICM could be the presence of typically extensive dysfunctional areas of myocardial skin damage; such regions are less pronounced or absent within patients with NIDCM [ 26 , 27 ].

From our meta-analysis, we could not identify a beneficial a result of bone marrow-derived stem cell therapy on 6MWT outcomes during follow-up. This finding might be attributable to the restricted improvement in left ventricular systolic function (3. 53%) observed in the cell group. This effect was statistically significant but clinically insufficient to produce a noticeable change within exercise capacity. Recent studies [ 28 , 29 ] possess reported that 6MWT distance is positively correlated with the particular magnitude of increase in cardiac output ( r   =  0. 63), plus inadequate output increase may therefore account for a lack of modify in 6MWT results after stem cell therapy.

Certain research has revealed that the possible of autologous bone marrow-derived stem cell therapy pertaining to cardiac repair may be limited by patient-related factors, such as age group and gender. Stem cell therapy in patients along with acute myocardial infarction has been particularly effective at improving LVEF for ageing patients. This phenomenon likely occurs since ageing patients are likely to suffer from impaired endothelium and to show inadequate physiological angiogenesis responses to ischaemia; thus, this kind of patients will tend to greatly benefit from supplementation with come cells [ 30 ]. Gender may be a significant determinant associated with stem cell function via the direct actions of intercourse steroids on these cells. A prior study discovered greater post-ischaemic myocardial functional recovery after an intracoronary infusion of female stem cells than after a good intracoronary infusion of male stem cells [ 31 ].


Significant heterogeneity has been noted among the trials with respect to left ventricular function plus quality of life. This heterogeneity was due to multiple factors, such as the number of patients enrolled, whether trials were single-centre or even multicentre studies, the number of cells injected, routes of shot, and the use of granulocyte colony-stimulating factor (G-CSF) therapy within three trials [ 5 , 6 , 9 ]. The cell types utilized in the included trials are limited to BM-CD34 cells plus BMMNCs. Nonetheless, because three original papers involving a hundred and seventy-eight patients used BM-CD34 cells as the cell source plus four trials involving 304 patients used BMMNCs, extra analyses would have been unreliable. Second, in this study, heart function referred only to systolic function. When more information are available, it would be interesting to explore the efficacy of come cells for improving diastolic function.